|
Cancer Nanotechnology Platform PartnershipsThe Cancer Nanotechnology Platform Partnerships are engaged in directed, product-focused research that aims to translate cutting-edge science and technology into the next generation of diagnostic and therapeutic tools. These platforms will serve as the core technologies for a wide array of specific applications that will ultimately benefit cancer patients. The twelve Platform Partnerships awarded funding apply strong interdisciplinary technical and oncology expertise to six key platform categories in nanotechnology:
The awarded programs are listed below: Detecting Cancer Early with Targeted Nano-probes for Vascular Signatures DNA-linked Dendrimer Nanoparticle Systems for Cancer Diagnosis and Treatment Hybrid Nanoparticles in Imaging and Therapy of Prostate Cancer Integrated System for Cancer Biomarker Detection Metallofullerene Nanoplatform for Imaging and Treating Infiltrative Tumor Multifunctional Nanoparticles in Diagnosis and Therapy of Pancreatic Cancer Nanotechnology Platform for Pediatric Brain Cancer Imaging and Therapy Nanotechnology Platform for Targeting Solid Tumors Nanotherapeutic Strategy for Multidrug Resistant Tumors Near-Infrared Fluorescence Nanoparticles for Targeted Optical Imaging Novel Cancer Nanotechnology Platforms for Photodynamic Therapy and Imaging Photodestruction of Ovarian Cancer: ErbB3 Targeted Aptamer-Nanoparticle Conjugate
|